rs10885122 — ADRA2A ADRA2A Beta-Cell cAMP Variant

Intergenic variant near ADRA2A

See your personal result for ADRA2A

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Stress Hormone Brake on Insulin Secretion

When your body is under stress, adrenaline floods the bloodstream and blood glucose rises sharply — a survival adaptation that makes energy available for fight or flight. One mechanism behind this glucose surge is the alpha-2A adrenergic receptor (ADRA2A) on pancreatic beta cells, which acts as a brake on insulin release when activated by catecholamines like norepinephrine. The rs10885122 variant is located in an intergenic region approximately 0.2 megabases from the ADRA2A gene on chromosome 10.

The Mechanism

ADRA2A encodes a Gi-coupled receptor11 Gi-coupled receptor
Gi proteins inhibit adenylate cyclase, reducing intracellular cAMP. cAMP is essential for the late stages of insulin granule trafficking to the beta cell membrane expressed on the surface of pancreatic beta cells. When norepinephrine or epinephrine binds ADRA2A, the receptor inhibits adenylate cyclase, reducing cyclic AMP (cAMP) levels inside the cell. Lower cAMP impairs the docking of insulin-containing granules to the plasma membrane, the key step in glucose-stimulated insulin secretion.

The Evidence

The variant was first identified as a fasting glucose locus in the landmark MAGIC consortium meta-analysis22 MAGIC consortium meta-analysis
Dupuis, Langenberg et al. 2010 — meta- analysis of 21 genome-wide association studies in 46,186 non-diabetic participants with replication in 76,558; identified 9 new loci for fasting glucose, with ADRA2A among them. The ADRA2A region was one of nine newly identified loci associated with fasting glucose, establishing the variant at the level of large-scale population genetics.

The biological mechanism was demonstrated by Rosengren et al.33 Rosengren et al.
Science 2010, PMID 19965390 — functionally validated in both rat congenic models and human islets, who showed that ADRA2A overexpression in beta cells causes glucose intolerance in rodents.

The clinical relevance was quantified in a randomized controlled trial by Cervin et al. 201444 randomized controlled trial by Cervin et al. 2014
50 T2D patients; 10 or 20 mg yohimbine administered at three separate visits; primary outcome Ins30 (insulin secretion at 30 min after oral glucose). Patients carrying the ADRA2A risk genotype had 25% lower baseline insulin secretion at 30 minutes versus non-carriers; administration of 20 mg yohimbine (an alpha-2A antagonist) enhanced secretion by 29%, restoring it to levels comparable with low-risk carriers. This is a rare example of a genetic variant directly dictating therapeutic response in a blinded trial.

Stress-induced hyperglycemia was investigated by Hiebert et al. 201655 Hiebert et al. 2016
retrospective study of 521 non-diabetic patients admitted after acute myocardial infarction; ten ADRA2A SNPs assessed; rs10885122 was the most significant. GG homozygotes had admission blood glucose 23% (geometric mean) higher than TT homozygotes; 26% of GG patients had glucose exceeding 140 mg/dL (the hyperglycemia threshold) versus only 11% of TT patients. This confirms that the genotype modulates real-world glucose regulation under catecholamine-surge conditions.

Practical Actions

For GG carriers — the large majority — the main implication is that fasting glucose and HbA1c are the appropriate biomarkers to track. Acute stress events (illness, surgery, myocardial infarction) can transiently amplify this brake as catecholamine levels surge, causing larger glucose excursions than would occur in TT individuals.

Interactions

The strongest interaction to document is between rs10885122 and the nearby ADRA2A 3' UTR variant rs553668. These two SNPs are not in linkage disequilibrium and appear to tag independent effects on the same gene. rs553668 (A allele) is the variant most directly associated with reduced insulin secretion and T2D risk in the Rosengren mechanistic studies, while rs10885122 shows the stronger fasting glucose signal in GWAS. The rare haplotype carrying both minor alleles (rs553668-A and rs10885122-T) was associated with significantly higher fasting glucose (p < 0.00001), though that finding did not survive permutation, suggesting the combination is too rare for statistical certainty.

TCF7L2 rs7903146 (the most established T2D GWAS variant, located ~1.6 Mb upstream on the same chromosome) operates through a completely different pathway — beta cell mass and incretin response — but both variants converge on impaired insulin secretion.

Genotype Interpretations

What each possible genotype means for this variant.

GG Standard Brake Sensitivity Normal

Common genotype — standard alpha-2A adrenergic suppression of insulin secretion

You carry two copies of the G allele, the most common configuration at this locus. Approximately 77% of people of European descent share this genotype. Fasting glucose is nominally higher than in T-allele carriers on a population-wide basis, but this represents the baseline against which the protective T allele was discovered — the GG state is the population norm, not a pathological outlier.

Under acute stress, catecholamine-driven suppression of insulin secretion follows the common pattern for this gene. If you carry additional T2D risk variants (such as TCF7L2 rs7903146) or have other metabolic risk factors, the cumulative effect on beta cell function is worth monitoring.

GT Partial Brake Relief Beneficial

One T allele — moderately reduced ADRA2A expression and slightly improved insulin secretion

You carry one copy of the protective T allele. Approximately 21% of Europeans share this heterozygous genotype. Your fasting glucose and insulin secretion capacity are expected to be intermediate between GG and TT individuals — you have some genetic protection but not the full effect seen in TT homozygotes.

In the myocardial infarction cohort study by Hiebert et al. (2016), heterozygous carriers showed intermediate admission glucose values between GG and TT groups.

TT Full Brake Relief Beneficial

Two T alleles — lowest ADRA2A expression, best insulin secretion capacity at this locus

You carry two copies of the rare protective T allele. Only about 2% of Europeans share this genotype. In the stress hyperglycemia study, TT individuals had admission blood glucose 23% lower (geometric mean) than GG homozygotes after acute myocardial infarction — a clinically meaningful difference in how the body responds to catecholamine surges.